|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **Variable** | **Univariate cause Specific Survival HR (95% CI)** | **p-value** | **Univariate overall Survival****HR (95% CI)** | **p-value** |
|  |  |  |  |  |  |
| **Age**\*\* |  |  |  |  |  |
|  | <60 years | Reference |  | Reference |  |
|  | ≥60 years | 2.07 (1.89 – 2.27) | <0.001 | 2.81 (2.61 – 3.03) | <0.001 |
| **Gender**\*\* |  |  |  |  |  |
|  | Female | Reference |  | Reference |  |
|  | Male | 1.21 (1.11 – 1.31) | <0.001 | 1.14 (1.07 – 1.21) | <0.001 |
| **Ethnicity¥** |  |  |  |  |  |
|  | Non-Hispanic white | Reference |  | Reference |  |
|  | Non-Hispanic black | 1.21 (1.04 – 1.41) | 0.01 | 1.18 (1.04 – 1.32) | 0.007 |
|  | Hispanic | 1.04 (0.92 – 1.18) | 0.52 | 0.90 (0.81 – 0.99) | 0.039 |
|  | Others | 0.98 (0.85 – 1.12) | 0.74 | 0.90 (0.81 – 1.00) | 0.048 |
| **Staging**\*\* |  |  |  |  |  |
|  | Stage 1 | Reference |  | Reference |  |
|  | Stage 2 | 1.64 (1.48 – 1.80) | <0.001 | 1.25 (1.16 – 1.34) | <0.001 |
|  | Stage 3 | 1.92 (1.63 – 2.26) | <0.001 | 1.38 (1.21 – 1.58) | <0.001 |
|  | Stage 4 | 2.65 (2.40 – 2.91) | <0.001 | 1.83 (1.70 – 1.98) | <0.001 |
| **Site¥** |  |  |  |  |  |
|  | Small Intestine | Reference |  | Reference |  |
|  | Large Intestine | 0.95 (0.88 – 1.03) | 0.23 | 1.04 (0.98 – 1.11) | 0.1 |
| **Histology**\*\* |  |  |  |  |  |
|  | DLBCL | Reference |  | Reference |  |
|  | Follicular Lymphoma | 0.22 (0.19 – 0.26) | <0.001 | 0.35 (0.31 – 0.38) | <0.001 |
|  | MALTOMA | 0.25 (0.22 – 0.30) | <0.001 | 0.47 (0.43 – 0.53) | <0.001 |
|  | Mantle Cell lymphoma | 0.88 (0.75 – 1.03) | 0.11 | 0.83 (0.73 – 0.94) | 0.004 |
|  | Other B-cell NHL | 0.87 (0.70 – 1.10) | 0.25 | 0.99 (0.83 – 1.17) | 0.870 |
|  | NHL, NOS | 0.90 (0.77 – 1.04) | 0.15 | 0.98 (0.88 – 1.10) | 0.765 |
|  | Burkitt Lymphoma | 1.00 (0.83 – 1.19) | 0.96 | 0.75 (0.65 – 0.89) | <0.001 |
|  | T−Cell NHL | 2.96 (2.61 – 3.37) | <0.001 | 2.42 (2.15 – 2.72) | <0.001 |
| **Treatment**\*\* |  |  |  |  |  |
|  | None | Reference |  | Reference |  |
|  | Surgery | 1.21 (1.08 – 1.37) | 0.001 | 1.31 (1.20 – 1.43) |  |
|  | Chemotherapy | 1.13 (1.00 – 1.27) | 0.54 | 1.00 (0.91 – 1.10) | 1.00 |
|  | Chemotherapy and surgery | 0.98 (0.87 – 1.10) | 0.70 | 0.87 (0.79 - .95) | 0.002 |
| **Year of Diagnosis**\*\* |  |  |  |  |  |
|  | 2000 – 2005 | Reference |  | Reference |  |
|  | 2006 - 2010 | 0.81 (0.74 – 0.89) | <0.001 | 0.84 (0.78 – 0.90) | <0.001 |
|  | 2011 - 2015 | 0.69 (0.63 – 0.77) | <0.001 | 0.76 (0.70 – 0.82) | <0.001 |

**Suppl 5.** Univariate analysis of the survival factors for cause specific and overall survival for all PINHL patients. ¥ Cause specific cox proportional hazard model was not significant for site (p-value – 0.2) and ethnicity (p-value – 0.1). Hence, Not included for multivariate analysis. \*\*Cox PH model p-value – <0.001.